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1. Synonyms 
MBC 
2. Definition 
Male breast cancer (MBC). 
3. Clinical Ffeatures 
x Incidence: Breast cancer in men is rare and accounts for 1% of all breast cancer diagnoses. In the 
UK, some 350 men are diagnosed annually with around 2470 in the USA. Data from cancer 
registries in the UK and USA suggests that the numbers of men receiving a breast cancer 
diagnosis has been rising gradually since the 1970s. 
x Age: Typically over 60, although all ages can be affected. 
x Sex: Breast cancer is found predominantly in women, but it can also affect men. Breast cancer in 
men is around 100 times less common than it is in women. 
x Site: Breast tissue in men is typically situated directly behind the nipple. 
x Clinical presentation: A unilateral, firm, painless, or minimally tender mass behind or adjacent to 
nipple or in axilla; changes in appearance of the nipple, e.g., inversion; and nipple discharge or 
bleeding. Because MBC is perceived by the majority of general public as a gender-specific 
condition, men often postpone presenting to doctors with symptoms, which can result in delays in 
diagnosis. The diagnostic pathway for MBC is similar to that used in women where breast cancer 
is suspected. While screening mammography is not recommended, due to small amounts of breast 
tissue in men, paradoxically this makes palpation of a suspicious lesion easier. Diagnosis is based 
on physical examination and biopsy. Sentinel lymph node biopsy is also used to identify positive 
nodes (´Sentinel Nodeµ). 
x Treatment: The absence of gender-specific trials for breast cancer means that men are treated in 
exactly the same way as women. Usually this mastectomy is followed by chemotherapy and 
radiotherapy. Some men opt for breast-conserving surgery, if appropriate, because of reduced 
morbidity and a better cosmetic outcome. As most MBCs express estrogen receptor, they are 
suitable for treatment with endocrine therapy, predominantly adjuvant tamoxifen. Data from 
clinical trials such as ATAC, in which the efficacies of aromatase inhibitors (AIs) were compared 
to tamoxifen, have revolutionizsed the treatment of breast cancer in post-menopausal women, 
such that AIs are now considered first- line therapy. Despite the fact that aromatase is expressed in 
MBC, initial case series have shown negative or equivocal results meaning the efficacy of 
aromatase inhibition in men has been questioned. Because of the increase in testosterone seen 
after aromatase inhibition, this may overcome the effect of AI blockade, by saturating the enzyme 
pathway with substrate, resulting in only a modest suppression of estrogen. Hence LHRH agonists 
are required to reduce excessive substrate and maximizse the effect of aromatase inhibition. As a 
result, AIs are generally contraindicated in MBC, unless used with medical or surgical 
orchiectomy. 
x Outcome: About 80 men will die of breast cancer in the UK each year. In the USA, this is around 
460. Survival rates for MBC are generally assumed to be lower than female breast cancer, 
probably as a result of presentation at a more advanced stage than in women. However, in general, 
studies in which male and female breast cancer are matched for key prognostic factors (size, 
grade, and lymph node status), have refuted this, with outcome almost identical between genders. 
 
4. Macroscopy 
Most specimens are mastectomies (Fig. 1a) with either sentinel node biopsy or axillary node clearance 
according to the pre surgical nodal assessment results. The macroscopic tumours are often large, with 
frequent skin and nipple involvement (Fig. 1b). Similar to the female type, the tumour may appear 
circumscribed and, infiltrative or show cystic changes. 
Fig. 1 (a) A mastectomy specimen with orientation sutures. It includes fibrofatty breast tissue with an 
overlying nipple bearing ellipse of the skin. The surgical margin is painted. (b) Slicing of the posterior 
surface shows a well-defined, graeyish- white haemorrhagic tumour. The tumour is clear of surgical 
margins 
5. Microscopy 
The main histological types and their frequency in MBC areis shown in Table 1. Of these, the commonest 
type of MBC is invasive ductal carcinoma of no special type (NST)  Invasive Carcinoma NST   of grade 2 
differentiation (Fig. 2). The tumours comprise nests and trabecula of malignant cells within fibrous 
stroma. Invasive lobular carcinoma is extremely rare and so is lobular carcinoma in situ. Compared with 
female breast cancer, incidence of papillary carcinoma (both intraductal and invasive) and mucinous 
carcinoma is higher in the male breast (Shaaban, et al. 2012). Ductal carcinoma in situ (DCIS; ´Ductal 
Carcinoma In Situµ) is reported in 5²15% of cases. Reporting of MBC and cancer datasets isare the same 
as for female breast cancer. 
Fig. 2 (H&E) image of the most frequent type of MBC, ductal carcinoma NST 
6. Immunophenotype 
A meta-analysis of 1986 cases, designed to identify common features of MBC, showed that MBC is 
typically ERɲ- and PR-positive, with HER2 expression infrequent (Humphries, et al. 2017). This is in 
line with preliminary results reported from the EORTC10085, TBCRC, BIG, and the NABCG 
International Male Breast Cancer Program and other smaller studies from single centers. This is 
illustrated in Table 2. As with female breast cancer, ERɲ and PR are used to guide treatment and 
prognosis in MBC (´Hormone Receptors in Breast Cancerµ). Other biomarkers that have been examined 
in MBC using immunohistochemistry include: AR, ERɴ1, ERɴ2, ERɴ5, Bcl-2, p53, E-cadherin, Ki67, 
survivin (both in the nucleus and cytoplasm), prolactin, and FOXA1. While these biomarkers are not 
unique to MBC, some of them, e.g., AR, is frequently expressed at relativity high levels in men. Although 
AR is currently not used for routine diagnostics or management in MBC, its relative abundance suggests 
that this could be used as a therapeutic target for anti-androgen therapies. Examples of ERɲ, PR, and AR 
expression in MBC are shown in Fig. 3. 
Fig. 3 Immunohistochemical examples of hormone receptors which are commonly expressed in MBC. 
ERɲ (a), PR (b), and AR (c) are frequently expressed 
Although ERɲ expression is higher in MBC than in female breast cancer (typically in approximately 80% 
of MBCs vs. 60²70% of female breast cancers), it has been proposed that not all ERɲ-positive MBCs 
behave in the same way as their female counterparts. This is founded through observations of different 
grouping of hormone receptor patterns when applying hierarchical clustering. In female breast cancers, 
PR and ERɲ clustered together, while in MBC, ERɲ clustered together with ERɴ and AR, with PR 
clustering independently (Shaaban, et al., 2012). Further cluster analysis in MBC showed significant 
correlation of ERɲ, AR, and FOXA1 (Humphries, et al., 2017). 
 
A number of cell cycle proteins have also been examined in MBC. Enhanced proliferation seems to be 
associated with poorer outcome in MBC, exemplified analysis of proliferation by mitotic count, and the 
expression of cyclins -A, -B, and îD1 biomarkers. 
 7. Molecular Ffeatures 
MBC is identical to female breast cancer histologically;, however data from molecular profiling studies 
using a variety of platforms is starting to suggest there may be underlying gender-specific biological 
differences in their genomic landscapes, both genetically and epigenetically. 
 
As reported above, in general, the main histological subtype observed in MBC is ductal NST with the 
most common phenotype ER- and/or PR-positive;, HER2-negative, which falls into the luminal A-like 
subgroup, is used to stratify female breast cancer. However, one of the first gene profiling studies to 
compare male and female breast cancer showed two unique subgroups of MBC, termed luminal M1 and 
luminal M2 (Johansson, et al. 2012). These differed from the conventional molecular classifications 
observed in female breast cancer. Consequently, the same group reported differential driver genes in 
MBC vs. female breast cancer. Somatic genetic alterations typically seen in ERɲ-positive/HER2-negative 
female breast cancers (the most common phenotype seen in MBC), e.g., PIK3CA and TP53 mutations 
and 16q loss, were much less frequent in subtype-matched MBC, suggesting that MBC is driven by 
different somatic changes (Piscuoglio, et al. 2016). In a number of smaller studies, gender-specific 
differentially expressed genes, including those involved in translation, cell migration / motility, immune 
response, membrane transport, apoptosis, and energy metabolism, have been reported, adding weight to 
the hypothesis that male and female breast cancers are biologically distinct. 
 
Promoter hypermethylation has been reported in MBC with methylation of a number of genes that are 
known to act as tumor suppressors. Accumulation of methylated genes and an overall high methylation 
pattern wereas correlated with a more aggressive phenotype and poorer survival. Interestingly, RASSF1A, 
a well- characterizsed tumor suppressor gene, was significantly more frequently methylated in MBC than 
female breast cancer, providing further evidence of likely biological differences between genders. 
Expression of microRNAs (miRs), small noncoding RNAs that alter gene expression at the post-
transcriptional level, has been examined in MBC. Differential expression of several miRNAs has been 
reported between gynaecomastia and MBC and also between MBC and female breast cancer. Despite 
these observational reports, the role of miRs in MBC, and if this may contrast from female breast cancer, 
has not been studied fully. 
 
Germline mutations of BRCA2 and, to a lesser extent, BRCA1, are associated with increased risk of men 
developing breast cancer (approximately 5²10% and 1²5%, respectively). A genome-wide association 
study of MBC identified a SNP in RAD51B which was associated with MBC susceptibility, but there is 
evidence that common variants associated with female breast cancer may also impact MBC risk (Orr, et 
al. 2012). More recent genotyping of 1802 male carriers of BRCA1/2 mutations showed that weighted 
polygenic risk scores based on 88 female breast cancer susceptibility variants were similarly associated 
with breast cancer risk in men (Lecarpentier, et al. 2017). A large ongoing study into the causes of MBC 
has identified several genetic variations associated with risk of developing the disease. These genetic 
variations appear to have a different effect on risk in on risk between genders, lending further support to 
the idea that the biology of breast cancer is diverse in men and women. 
 
8. Differential Ddiagnosis 
The most important differentials are gynecomastia, a benign enlargement of the male breast 
(´Gynecomastiaµ) and metastases to the breast, such as metastatic prostatic carcinoma, melanoma, «etc. 
Gynaecomastia may present with florid hyperplasia of the mammary ducts which can mimic in situ 
carcinoma particularly on small biopsy or in cytological preparations. Attention to the architectural 
features of hyperplasia, admixture of luminal and basaloid cells, and the absence of significant atypia 
support a benign diagnosis. Basal cytokeratins such as CK5 and CK14 show a 3 three- layered ductal 
epithelium in gynaecomastia (Kornegoor, et al. 2012) and negative staining in DCIS. Metastases to the 
breast should be identified by clinical correlation, unusual histological features, and a suitable panel of 
immunohistochemical biomarkers. 
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Table 1 Main histological subtypes observed in MBC and their relative frequencies 
Histology % Frequency 
Ductal NST 85 
Lobular 1²2 
Papillary 3²5 
Mucinous 1 
Medullary 0.5 
Cribriform 0.5²1 
Tubular 0.5 
Mixed 5 
 
Data was obtained from several published articles, including the Veterans Affairs (VA) Central Cancer 
Registry and (Shaaban et al. 2012). 
 
Table 2 Overview of the clinicopathological features of MBC in sixteen 16 published studies examining a 
total of 1986 cases from 1996² to 2017 
Feature Number (%) 
Histology 
Ductal 1615 (84) 
Lobular 19 (1) 
Other 239 (12) 
N/A 60 (3) 
Grade 
1 239 (13) 
2 872 (48) 
3 597 (33) 
N/A 115 (6) 
Node 
+ 734 (42) 
î 742 (42) 
N/A 275 (16) 
ERɲ 
+ 1584 (86) 
î 193 (10) 
N/A 74 (4) 
PR 
+ 1321 (72) 
î 436 (24) 
N/A 84 (5) 
HER2 
+ 160 (9) 
î 1319 (77) 
N/A 241 (14) 
Data adapted from Humphries et al., 2017, where details on specific studies can be found. 
N/A not available. 
